<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03442972</url>
  </required_header>
  <id_info>
    <org_study_id>GLP-2 Biopsy 16-6368</org_study_id>
    <nct_id>NCT03442972</nct_id>
  </id_info>
  <brief_title>Glucagon-like Peptide-2 Mediated Secretion of Stored Enteral Lipids</brief_title>
  <acronym>GLP-2 Biopsy</acronym>
  <official_title>Investigating the Release of Stored Enteral Lipids in Response to a Single Subcutaneous Dose of Analogue Glucagon-like Peptide-2 in Humans</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Kensington Screening Clinic</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Health Network, Toronto</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Some of the fat (triglyceride) from the food humans eat gets stored in the bowel. This&#xD;
      triglyceride can then be released into the blood when another meal is consumed or in response&#xD;
      to hormones. How the gut hormone glucagon-like peptide-2 (GLP-2) releases the triglyceride&#xD;
      from the gut is not known. The research team in this study is interested in finding out how&#xD;
      teduglutide (a degradation resistant form of GLP-2) releases stored triglyceride from the gut&#xD;
      by studying samples from patients undergoing endoscopy and small bowel biopsy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The release of stored enteral lipids will be investigated in 30 patients undergoing upper&#xD;
      gastrointestinal endoscopy and duodenal biopsy for clinical indications. Patients undergoing&#xD;
      the procedure will be recruited. Participants will have a high fat liquid meal as breakfast.&#xD;
      5 hours later, participants will be randomly assigned to receive either a subcutaneous&#xD;
      injection of placebo (n=15) or a subcutaneous injection of the Health Canada approved&#xD;
      glucagon-like peptide-2 (GLP-2) analogue (teduglutide, Revestive®, Shire Canada)(n=15&#xD;
      different subjects). 1 hour later, a duodenal biopsy specimen will be obtained from 2-3&#xD;
      sample sites,snap frozen in dry ice and stored at -80°C for further analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 17, 2019</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be randomly assigned to receive either teduglutide or placebo as a single subcutaneous injection, 1 hour prior to duodenal biopsy</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
    <masking_description>Single-blinded study with participant blinded to treatment</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Release of enteral lipids in response to teduglutide</measure>
    <time_frame>6 hours</time_frame>
    <description>To quantify the difference in amount of enteral lipids between GLP-2 and placebo treatment</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Hyperlipidemias</condition>
  <arm_group>
    <arm_group_label>Teduglutide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Teduglutide, up to 0.05mg/kg, subcutaneous, single dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo, subcutaneous, single dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teduglutide</intervention_name>
    <description>Teduglutide</description>
    <arm_group_label>Teduglutide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men and women, aged 18 to 60 years requiring endoscopy and duodenal biopsies for&#xD;
             clinical indications, with no contraindications to the procedure, as judged by Dr.&#xD;
             Bookman of the Kensington Screening Clinic, Toronto, ON, Canada&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with active inflammatory bowel disease&#xD;
&#xD;
          -  Patients with pre-existing Celiac disease, exocrine pancreatic insufficiency or small&#xD;
             bowel malabsorption&#xD;
&#xD;
          -  Patients with active bowel malignancy&#xD;
&#xD;
          -  Patients with diabetes mellitus or known/ suspected motility disorders of the gut&#xD;
&#xD;
          -  Patients with decompensated liver disease&#xD;
&#xD;
          -  Patients on ezetimibe or bile acid sequestrants&#xD;
&#xD;
          -  Patients who are pregnant or breastfeeding.&#xD;
&#xD;
          -  Patients with renal disease&#xD;
&#xD;
          -  Patients on benzodiazepine&#xD;
&#xD;
          -  Unstable cardiac or respiratory disease&#xD;
&#xD;
          -  Any changes to medication in the preceding month&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gary Lewis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UHN</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Toronto General Hopital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2C4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kensington Screening Clinic</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 3A9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 2, 2018</study_first_submitted>
  <study_first_submitted_qc>February 16, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2018</study_first_posted>
  <last_update_submitted>April 27, 2021</last_update_submitted>
  <last_update_submitted_qc>April 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Intestinal lipoprotein</keyword>
  <keyword>Duodenal biopsy</keyword>
  <keyword>Gut Peptide</keyword>
  <keyword>Chylomicrons</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teduglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

